What is the recommended management for a patient diagnosed with polycythemia vera, including phlebotomy, aspirin therapy, and criteria for initiating cytoreductive treatment?

Management of Polycythemia Vera

All patients with polycythemia vera must receive phlebotomy to maintain hematocrit below 45% combined with daily low-dose aspirin (81-100 mg), and cytoreductive therapy should be added for high-risk patients (age >60 years or history of thrombosis). 1

Universal Treatment for All PV Patients

Phlebotomy Protocol

• Target hematocrit: <45% - this is non-negotiable based on the CYTO-PV trial, which demonstrated a nearly 4-fold reduction in cardiovascular death and major thrombotic events (2.7% vs 9.8%) when maintaining hematocrit <45% compared to 45-50% 1
• Induction phase: Remove 300-450 ml weekly or twice weekly until target reached
• Maintenance phase: Same volume per session, with intervals determined by hematocrit levels 1
• While the trial used <45% for both sexes, consider individualizing to 42% for women or patients with persistent vascular symptoms 2

Aspirin Therapy

• Dose: 81-100 mg daily for all patients unless contraindicated 1, 2
• Critical caveat: Screen for acquired von Willebrand disease before starting aspirin if platelet count >1500 × 10⁹/L, as this increases bleeding risk 1
• Recent evidence suggests one-third of PV patients on once-daily aspirin show inadequate platelet inhibition 3; consider twice-daily dosing (81 mg BID) in patients with persistent microvascular symptoms or very high platelet counts
• When combined with anticoagulation: Be aware that aspirin plus anticoagulant increases hemorrhage risk 5-8 fold compared to aspirin alone (6.75 vs 1.40 per 100 patient-years) 4

Cardiovascular Risk Factor Management

Aggressively manage all modifiable cardiovascular risk factors in every patient 1

Risk Stratification and Cytoreductive Therapy

High-Risk Criteria (Cytoreduction REQUIRED)

Cytoreductive therapy is strongly recommended if ANY of the following apply 1:

Primary high-risk criteria:

• Age >60 years
• Prior thrombotic event

Additional indications for cytoreduction:

• Poor phlebotomy tolerance (frequent sessions causing symptoms)
• Symptomatic or progressive splenomegaly
• Severe disease-related symptoms (pruritus, night sweats, fatigue)
• Platelet count >1500 × 10⁹/L
• Leukocyte count >15 × 10⁹/L
• Symptomatic iron deficiency from phlebotomy (pica, mouth paresthesia, esophagitis, restless legs) that worsens hematocrit when iron is replaced 1

First-Line Cytoreductive Options

Hydroxyurea or Recombinant Interferon-α (rIFNα) are both acceptable first-line agents at any age 1

Choosing between them:

• Hydroxyurea: More commonly used, well-established efficacy

  • Use cautiously in young patients (<40 years) due to theoretical long-term leukemogenic concerns, though this risk is debated 2
  • The ECLAP study found older age and other alkylating agents (not hydroxyurea alone) were independent risk factors for leukemic transformation 2

• Interferon-α (including pegylated forms): Preferred for:

  • Younger patients who want to minimize any theoretical leukemia risk
  • Pregnant patients requiring cytoreduction 2
  • Patients seeking potential disease-modifying therapy (can reduce JAK2V617F allele burden) 5

Second-Line Cytoreductive Therapy

When to switch therapy - if patient develops 1:

• Intolerance or resistance to first-line agent (see specific criteria below)
• New thrombosis despite treatment
• Progressive splenomegaly or symptoms
• Acquired von Willebrand disease with bleeding

Resistance/Intolerance to Hydroxyurea is defined as ANY of 2:

1. Inability to maintain hematocrit <45% after 3 months on ≥2 g/day
2. Uncontrolled myeloproliferation (platelets >400 × 10⁹/L AND WBC >10 × 10⁹/L) after 3 months on ≥2 g/day
3. Failure to reduce massive splenomegaly by >50% after 3 months on ≥2 g/day
4. Cytopenias at lowest effective dose (ANC <1.0 × 10⁹/L OR platelets <100 × 10⁹/L OR hemoglobin <10 g/dL)
5. Leg ulcers or other unacceptable toxicities (mucocutaneous, GI, pneumonitis, fever)

Second-line options:

• Switch hydroxyurea to interferon-α, or vice versa 1
• Ruxolitinib (JAK1/JAK2 inhibitor): FDA/EMA approved for hydroxyurea-resistant or intolerant patients 1
  • Moderate quality evidence from RESPONSE trials
  • Reserve for patients who have failed both hydroxyurea and interferon, or for severe refractory pruritus/splenomegaly 6
• Busulfan: Consider as last resort in elderly patients with limited life expectancy 7

Low-Risk Disease Management

For patients <60 years with no thrombosis history:

• Phlebotomy + aspirin alone is sufficient 1, 2
• Do not initiate cytoreductive therapy unless additional high-risk features develop
• Monitor for disease progression and cardiovascular risk factors

Special Situations

Iron Deficiency from Phlebotomy

• If severe symptomatic iron deficiency develops, iron supplementation is indicated
• If iron replacement causes hematocrit to rise unacceptably, this mandates starting cytoreductive therapy 1

Thrombocytosis Management

• Extreme thrombocytosis (>1500 × 10⁹/L) warrants cytoreduction
• Periods of thrombocytosis >600 × 10⁹/L are associated with increased hemorrhage risk (HR 2.25) 4

Disease Progression

Monitor for transformation to myelofibrosis or acute leukemia; bone marrow biopsy should be performed before initiating cytoreductive therapy to establish baseline 2